Top

Published in:

09-11-2023 | Levodopa | Neurology and Preclinical Neurological Studies - Original Article

Levodopa may modulate specific speech impairment in Parkinson's disease: an fMRI study

Authors: Martina Mračková, Radek Mareček, Jiří Mekyska, Milena Košťálová, Irena Rektorová

Published in: Journal of Neural Transmission | Issue 2/2024

Abstract

Hypokinetic dysarthria (HD) is a difficult-to-treat symptom affecting quality of life in patients with Parkinson’s disease (PD). Levodopa may partially alleviate some symptoms of HD in PD, but the neural correlates of these effects are not fully understood. The aim of our study was to identify neural mechanisms by which levodopa affects articulation and prosody in patients with PD. Altogether 20 PD patients participated in a task fMRI study (overt sentence reading). Using a single dose of levodopa after an overnight withdrawal of dopaminergic medication, levodopa-induced BOLD signal changes within the articulatory pathway (in regions of interest; ROIs) were studied. We also correlated levodopa-induced BOLD signal changes with the changes in acoustic parameters of speech. We observed no significant changes in acoustic parameters due to acute levodopa administration. After levodopa administration as compared to the OFF dopaminergic condition, patients showed task-induced BOLD signal decreases in the left ventral thalamus (p = 0.0033). The changes in thalamic activation were associated with changes in pitch variation (R = 0.67, p = 0.006), while the changes in caudate nucleus activation were related to changes in the second formant variability which evaluates precise articulation (R = 0.70, p = 0.003). The results are in line with the notion that levodopa does not have a major impact on HD in PD, but it may induce neural changes within the basal ganglia circuitries that are related to changes in speech prosody and articulation.

Available only for authorised users

Abutalebi J, Rosa PAD, Castro Gonzaga AK, Keim R, Costa A, Perani D (2013) The role of the left putamen in multilingual language production. Brain Lang 125:307–315. https://doi.org/10.1016/j.bandl.2012.03.009CrossRefPubMed

Arnold C, Gehrig J, Gispert S, Seifried C, Kell CA (2014) Pathomechanisms and compensatory efforts related to Parkinsonian speech. NeuroImage Clin 4:82–97. https://doi.org/10.1016/j.nicl.2013.10.016CrossRefPubMed

Berankova D, Janousova E, Mrackova M, Eliasova I, Kostalova M, Skutilova S, Rektorova I (2015) Addenbrooke’s cognitive examination and individual domain cut-off scores for discriminating between different cognitive subtypes of Parkinson’s disease. Parkinson Dis 2015:579417. https://doi.org/10.1155/2015/579417CrossRef

Brabenec L, Mekyska J, Galaz Z, Rektorova I (2017) Speech disorders in Parkinson’s disease: early diagnostics and effects of medication and brain stimulation. J Neural Transm 124:303–334. https://doi.org/10.1007/s00702-017-1676-0CrossRefPubMed

Brabenec L, Klobusiakova P, Barton M, Mekyska J, Galaz Z, Zvoncak V, Kiska T, Mucha J, Smekal Z, Kostalova M, Rektorova I (2019) Non-invasive stimulation of the auditory feedback area for improved articulation in Parkinson’s disease. Parkinsonism Relat Disord 61:187–192. https://doi.org/10.1016/j.parkreldis.2018.10.011CrossRefPubMed

Brabenec L, Klobusiakova P, Simko P, Kostalova M, Mekyska J, Rektorova I (2021) Non-invasive brain stimulation for speech in Parkinson’s disease: a randomized controlled trial. Brain Stimul 14(3):571–578. https://doi.org/10.1016/j.brs.2021.03.010CrossRefPubMed

Brown S, Laird AR, Pfordresher PQ, Thelen SM, Turkeltaub P, Liotti M (2009) The somatotopy of speech: phonation and articulation in the human motor cortex. Brain Cogn 70:31–41. https://doi.org/10.1016/j.bandc.2008.12.006CrossRefPubMedPubMedCentral

Cushnie-Sparrow D, Adams S, Abeyesekera A, Pieterman M, Gilmore G, Jog M (2018) Voice quality severity and responsiveness to levodopa in Parkinson’s disease. J Commun Disord 76:1–10. https://doi.org/10.1016/j.jcomdis.2018.07.003CrossRefPubMed

Elfmarková N, Gajdoš M, Mračková M, Mekyska J, Mikl M, Rektorová I (2016) Impact of Parkinson’s disease and levodopa on resting state functional connectivity related to speech prosody control. Parkinsonism Relat Disord 22:S52–S55. https://doi.org/10.1016/j.parkreldis.2015.09.006CrossRefPubMed

Fritsch M, Rangus I, Nolte CH (2022) Thalamic Aphasia: a review. Curr Neurol Neurosci Rep 22:855–865. https://doi.org/10.1007/s11910-022-01242-2CrossRefPubMedPubMedCentral

Frota S, Cruz M, Cardoso R, Guimarães I, Ferreira JJ, Pinto S, Vigário M (2021) (Dys)Prosody in Parkinson’s disease: effects of medication and disease duration on intonation and prosodic phrasing. Brain Sci. https://doi.org/10.3390/brainsci11081100CrossRefPubMedPubMedCentral

Gago MF, Garrett MC, Fonseca MR, Rosas MJ, Simões MF, Vieira S, Botelho F (2009) How do cognitive and axial motor signs correlate in Parkinson’s disease? A 6-year prospective study. J Neurol 256:1655–1662. https://doi.org/10.1007/s00415-009-5174-7CrossRefPubMed

Goberman AM, Blomgren M (2003) Parkinsonian speech disfluencies: effects of l-dopa-related fluctuations. J Fluen Disord 28:55–70. https://doi.org/10.1016/S0094-730X(03)00005-6CrossRef

Gómez-Vilda P, Mekyska J, Ferrández JM, Palacios-Alonso D, Gómez-Rodellar A, Rodellar-Biarge V, Galaz Z, Smekal Z, Eliasova I, Kostalova M, Rektorova I (2017) Parkinson disease detection from speech articulation neuromechanics. Front Neuroinform. https://doi.org/10.3389/fninf.2017.00056CrossRefPubMedPubMedCentral

Jacquemot C, Bachoud-Lévi A-C (2021) Striatum and language processing: where do we stand? Spec Issue Honour Jacques Mehler Cogn Found Ed 213:104785. https://doi.org/10.1016/j.cognition.2021.104785CrossRef

Klobusiakova P, Mekyska J, Brabenec L, Galaz Z, Zvoncak V, Mucha J, Rapcsak SZ, Rektorova I (2021) Articulatory network reorganization in Parkinson’s disease as assessed by multimodal MRI and acoustic measures. Parkinsonism Relat Disord 84:122–128. https://doi.org/10.1016/j.parkreldis.2021.02.012CrossRefPubMed

Klostermann F, Ehlen F (2013) Functional roles of the thalamus for language capacities. Front Syst Neurosci. https://doi.org/10.3389/fnsys.2013.00032CrossRefPubMedPubMedCentral

Košálová M, Mráčková M, Mareček R, Beránková D, Eliášová I, Koritakova E, Roubíčková J, Bednarik J, Rektorové I (2013) The 3F test dysarthric profile—normative speach values in Czech. Ceska Slov Neurol Neurochir 76:614–618

Kulisevsky J, García-Sánchez C, Berthier ML, Barbanoj M, Pascual-Sedano B, Gironell A, Estévez-González A (2000) Chronic effects of dopaminergic replacement on cognitive function in Parkinson’s disease: a two-year follow-up study of previously untreated patients. Mov Disord 15:613–626. https://doi.org/10.1002/1531-8257(200007)15:4%3c613::AID-MDS1005%3e3.0.CO;2-FCrossRefPubMed

Liotti M, Ramig LO, Vogel D (2003) Hypophonia in Parkinson’s disease: neural correlates of voice treatment revealed by PET. Neurology 60:432–440CrossRefPubMed

Maillet A, Krainik A, Debû B, Troprès I, Lagrange C, Thobois S, Pollak P, Pinto S (2012) Levodopa effects on hand and speech movements in patients with Parkinson’s disease: a FMRI study. PLoS One 7:e46541–e46541. https://doi.org/10.1371/journal.pone.0046541CrossRefPubMedPubMedCentral

Manes JL, Tjaden K, Parrish T, Simuni T, Roberts A, Greenlee JD, Corcos DM, Kurani AS (2018) Altered resting-state functional connectivity of the putamen and internal globus pallidus is related to speech impairment in Parkinson’s disease. Brain Behav 8(9):e01073. https://doi.org/10.1002/brb3.1073CrossRefPubMedPubMedCentral

Mekyska J, Janousova E, Gomez-Vilda P, Smekal Z, Rektorova I, Eliasova I, Kostalova M, Mrackova M, Alonso-Hernandez JB, Faundez-Zanuy M, López-de-Ipiña K (2015) Robust and complex approach of pathological speech signal analysis. Neurocomputing 167:94–111. https://doi.org/10.1016/j.neucom.2015.02.085CrossRef

Murphy E, Hoshi K, Benítez-Burraco A (2022) Subcortical syntax: reconsidering the neural dynamics of language. J Neurolinguist 62:101062. https://doi.org/10.1016/j.jneuroling.2022.101062CrossRef

New AB, Robin DA, Parkinson AL, Eickhoff CR, Reetz K, Hoffstaedter F, Mathys C, Sudmeyer M, Michely J, Caspers J, Grefkes C, Larson CR, Ramig LO, Fox PT, Eickhoff SB (2015) The intrinsic resting state voice network in Parkinson’s disease. Hum Brain Mapp 36:1951–1962. https://doi.org/10.1002/hbm.22748CrossRefPubMedPubMedCentral

Nieoullon A (2002) Dopamine and the regulation of cognition and attention. Prog Neurobiol 67:53–83. https://doi.org/10.1016/S0301-0082(02)00011-4CrossRefPubMed

Nutt JG, Carter JH, Van Houten L, Woodward WR (1997) Short- and long-duration responses to levodopa during the first year of levodopa therapy. Ann Neurol 42:349–355. https://doi.org/10.1002/ana.410420311CrossRefPubMed

Pichon S, Kell CA (2013) Affective and sensorimotor components of emotional prosody generation. J Neurosci 33:1640. https://doi.org/10.1523/JNEUROSCI.3530-12.2013CrossRefPubMedPubMedCentral

Rektorová I (2010) Effects of dopamine agonists on neuropsychiatric symptoms of Parkinson’s disease. Neurodegener Dis 7:206–209. https://doi.org/10.1159/000295665CrossRefPubMed

Rektorová I, Rektor I, Bareš M, Dostál V, Ehler E, Fanfrdlová Z, Fiedler J, Klajblová H, Kulišt’ák P, Ressner P, Svátová J, Urbánek K, Velísková J (2005) Cognitive performance in people with Parkinson’s disease and mild or moderate depression: effects of dopamine agonists in an add-on to l-dopa therapy. Eur J Neurol 12:9–15. https://doi.org/10.1111/j.1468-1331.2004.00966.xCrossRefPubMed

Rektorova I, Barrett J, Mikl M, Rektor I, Paus T (2007) Functional abnormalities in the primary orofacial sensorimotor cortex during speech in Parkinson’s disease. Mov Disord 22:2043–2051. https://doi.org/10.1002/mds.21548CrossRefPubMed

Rektorova I, Mekyska J, Janousova E, Kostalova M, Eliasova I, Mrackova M, Berankova D, Necasova T, Smekal Z, Marecek R (2016) Speech prosody impairment predicts cognitive decline in Parkinson’s disease. Parkinsonism Relat Disord 29:90–95. https://doi.org/10.1016/j.parkreldis.2016.05.018CrossRefPubMed

Rusz J, Tykalová T, Klempíř J, Čmejla R, Růžička E (2016) Effects of dopaminergic replacement therapy on motor speech disorders in Parkinson’s disease: longitudinal follow-up study on previously untreated patients. J Neural Transm 123:379–387. https://doi.org/10.1007/s00702-016-1515-8CrossRefPubMed

Rusz J, Tykalova T, Novotny M, Zogala D, Sonka K, Ruzicka E, Dusek P (2021) Defining speech subtypes in de novo Parkinson disease. Neurology 97:e2124. https://doi.org/10.1212/WNL.0000000000012878CrossRefPubMed

Rusz J, Tykalová T, Novotný M, Zogala D, Růžička E, Dušek P (2022) Automated speech analysis in early untreated Parkinson’s disease: Relation to gender and dopaminergic transporter imaging. Eur J Neurol 29:81–90. https://doi.org/10.1111/ene.15099CrossRefPubMed

Skodda S, Visser W, Schlegel U (2010) Short- and long-term dopaminergic effects on dysarthria in early Parkinson’s disease. J Neural Transm 117:197–205. https://doi.org/10.1007/s00702-009-0351-5CrossRefPubMed

Steurer H, Schalling E, Franzén E, Albrecht F (2022) Characterization of mild and moderate dysarthria in Parkinson’s disease: behavioral measures and neural correlates. Front Aging Neurosci. https://doi.org/10.3389/fnagi.2022.870998CrossRefPubMedPubMedCentral

Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653. https://doi.org/10.1002/mds.23429CrossRefPubMed

Tremblay P, Dick AS (2016) Broca and Wernicke are dead, or moving past the classic model of language neurobiology. Brain Lang 162:60–71. https://doi.org/10.1016/j.bandl.2016.08.004CrossRefPubMed

Tykalova T, Novotny M, Ruzicka E, Dusek P, Rusz J (2022) Short-term effect of dopaminergic medication on speech in early-stage Parkinson’s disease. Npj Parkinson Dis 8:22. https://doi.org/10.1038/s41531-022-00286-yCrossRef

Wahl M, Marzinzik F, Friederici AD, Hahne A, Kupsch A, Schneider G-H, Saddy D, Curio G, Klostermann F (2008) The human thalamus processes syntactic and semantic language violations. Neuron 59:695–707. https://doi.org/10.1016/j.neuron.2008.07.011CrossRefPubMed

Ziegler W, Ackermann H (2013) Neuromotor speech impairment: it’s all in the talking. Folia Phoniatr Logop 65:55–67. https://doi.org/10.1159/000353855CrossRefPubMed

Title: Levodopa may modulate specific speech impairment in Parkinson's disease: an fMRI study
Authors: Martina Mračková
Radek Mareček
Jiří Mekyska
Milena Košťálová
Irena Rektorová
Publication date: 09-11-2023
Publisher: Springer Vienna
Keywords: Levodopa
Parkinson's Disease
Dysarthria
Published in: Journal of Neural Transmission / Issue 2/2024
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-023-02715-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Levodopa may modulate specific speech impairment in Parkinson's disease: an fMRI study

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2024

Understanding depression with amyotrophic lateral sclerosis: a short assessment of facts and perceptions

Constipation and pain in Parkinson’s disease: a clinical analysis

Therapeutic use of medical Cannabis in neurological diseases: a clinical update

Neurogenic orthostatic hypotension in Parkinson’s disease: is there a role for locus coeruleus magnetic resonance imaging?

Sexual dysfunction in men with young onset Parkinson's disease

Baseline prevalence and longitudinal assessment of autonomic dysfunction in early Parkinson’s disease